STAT+: Pharmalittle: J&J drops out of bidding for Horizon; FDA takes a harder line on fast-track approvals

J&J said it does not intend to make an offer for Horizon Therapeutics, days after the developer of autoimmune- and inflammatory-disease medicines revealed they were in talks.